PT2134685E - Derivados de índole não substituídos na posição 7 como inibidores de mcl-1 - Google Patents

Derivados de índole não substituídos na posição 7 como inibidores de mcl-1 Download PDF

Info

Publication number
PT2134685E
PT2134685E PT87459343T PT08745934T PT2134685E PT 2134685 E PT2134685 E PT 2134685E PT 87459343 T PT87459343 T PT 87459343T PT 08745934 T PT08745934 T PT 08745934T PT 2134685 E PT2134685 E PT 2134685E
Authority
PT
Portugal
Prior art keywords
nonsubstituted
mcl
inhibitors
indole derivatives
indole
Prior art date
Application number
PT87459343T
Other languages
English (en)
Inventor
Milan Bruncko
Xiaohong Song
Zhi-Fu Tao
Hong Ding
Steven W Elmore
David Madar
Xilu Wang
Andrew J Souers
Aaron R Kunzer
Cheol-Min Park
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PT2134685E publication Critical patent/PT2134685E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT87459343T 2007-04-16 2008-04-16 Derivados de índole não substituídos na posição 7 como inibidores de mcl-1 PT2134685E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91204907P 2007-04-16 2007-04-16
US94968307P 2007-07-13 2007-07-13

Publications (1)

Publication Number Publication Date
PT2134685E true PT2134685E (pt) 2015-11-25

Family

ID=39683700

Family Applications (1)

Application Number Title Priority Date Filing Date
PT87459343T PT2134685E (pt) 2007-04-16 2008-04-16 Derivados de índole não substituídos na posição 7 como inibidores de mcl-1

Country Status (11)

Country Link
US (2) US7981888B2 (pt)
EP (1) EP2134685B1 (pt)
JP (2) JP5496876B2 (pt)
CN (1) CN101711235A (pt)
CA (2) CA2682354C (pt)
DK (1) DK2134685T3 (pt)
ES (1) ES2550753T3 (pt)
MX (1) MX2009011210A (pt)
PL (1) PL2134685T3 (pt)
PT (1) PT2134685E (pt)
WO (1) WO2008130970A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743224A (zh) 2007-04-16 2010-06-16 雅培制药有限公司 7-取代的吲哚mcl-1抑制剂
AU2009326259A1 (en) 2008-12-08 2011-07-28 Boehringer Ingelheim International Gmbh Compounds for treating cancer
NZ593537A (en) * 2008-12-19 2013-07-26 Genentech Inc Isoquinoline derivatives and methods of use
AU2009335818A1 (en) 2008-12-19 2011-07-21 Abbvie Inc. Compounds and methods of use
JP5937968B2 (ja) 2010-01-29 2016-06-22 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｍｃｌ‐１を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2567698B1 (en) 2011-09-07 2014-02-12 Rheinische Friedrich-Wilhelms-Universität Bonn GPR 17 agonists and screening assay
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2827864B1 (en) * 2012-03-20 2020-09-30 Dana-Farber Cancer Institute, Inc. Inhibition of mcl-1 and/or bfl-1/a1
WO2014026330A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014047427A2 (en) 2012-09-21 2014-03-27 Vanderbilt University Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
US10005728B2 (en) 2013-08-28 2018-06-26 Vanderbilt University Substituted indole Mcl-1 inhibitors
EP3122353B1 (en) * 2014-03-27 2020-10-28 Vanderbilt University Substituted indole mcl-1 inhibitors
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
US20180291373A1 (en) 2014-10-29 2018-10-11 The Walter And Eliza Hall Institute Of Medical Research Use of therapeutic agents
EP3256450B1 (en) 2015-02-11 2020-12-02 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
US10463649B2 (en) 2015-06-08 2019-11-05 Texas Tech University System Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
CA3002853A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
JP2018535958A (ja) 2015-10-27 2018-12-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用
AU2016344111A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
US11866409B2 (en) * 2015-11-02 2024-01-09 Carmel-Haifa University Economic Corporation Ltd. Apoptosis related protein in the tgf-beta signaling pathway (ARTS) mimetic compounds, compositions, methods and uses thereof in induction of differentiation and/or apoptosis of premalignant and malignant cells, thereby restoring their normal-like phenotype
CN109153643B (zh) * 2016-03-04 2022-06-21 范德比尔特大学 取代的吲哚mcl-1抑制剂
TWI742074B (zh) 2016-04-22 2021-10-11 瑞典商阿斯特捷利康公司 Mcl-1抑制劑及其使用方法
WO2017198341A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
CN109715632B (zh) 2016-05-19 2021-10-26 拜尔公开股份有限公司 大环吲哚衍生物
JP2020518563A (ja) * 2017-04-30 2020-06-25 ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 抗ガン幹細胞性薬物
CN111757884B (zh) 2017-11-17 2023-12-19 拜耳股份公司 取代的大环吲哚衍生物
EP3710456B1 (en) 2017-11-17 2022-09-21 The Broad Institute, Inc. Macrocyclic indole derivatives
EP3710449B1 (en) 2017-11-17 2022-07-06 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer
EP3710447A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
US11478451B1 (en) 2017-11-17 2022-10-25 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
US11447504B2 (en) 2017-11-17 2022-09-20 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
CA3113917A1 (en) * 2018-09-30 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. Indole macrocyclic derivative, preparation method therefor and application thereof in medicine
WO2020103864A1 (en) * 2018-11-22 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic indoles as mcl-1 inhibitors
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
WO2021092061A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Combination treatment for senescence-associated diseases
EP4061820A1 (en) 2019-11-21 2022-09-28 Janssen Pharmaceutica NV Macrocyclic sulfonyl derivatives as mcl-1 inhibitors
CN114728985A (zh) 2019-11-21 2022-07-08 詹森药业有限公司 作为mcl-1抑制剂的大环吲哚衍生物
TW202134213A (zh) 2019-11-29 2021-09-16 日商小野藥品工業股份有限公司 具有水解磷脂酸受體作動活性之化合物及其醫藥用途
TW202144368A (zh) * 2020-03-30 2021-12-01 大陸商江蘇恒瑞醫藥股份有限公司 吲哚類大環衍生物的結晶形式及其製備方法
MX2022015005A (es) 2020-05-29 2023-01-04 Janssen Pharmaceutica Nv Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1.
CN115943147A (zh) 2020-06-19 2023-04-07 詹森药业有限公司 N-连接的大环7-(吡唑-5-基)-吲哚衍生物作为mcl-1抑制剂
KR20240019330A (ko) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항체 약물 접합체의 조합
KR20240019283A (ko) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항암제의 병용

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632805A (en) 1967-12-08 1972-01-04 Sumitomo Chemical Co Process for producing 1-aminoalkyl-benzodiazepine derivatives
FR2187318B1 (pt) 1972-06-08 1975-06-20 Delalande Sa
US4994477A (en) * 1988-03-24 1991-02-19 Abbott Laboratories Heterocyclic renin inhibitors
ATE255090T1 (de) * 1996-08-01 2003-12-15 Merckle Gmbh Acylpyrroldicarbonsäuren und acylindoldicarbonsäuren sowie ihre derivate als hemmstoffe der cytosolischen phospholipase a2
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
DE69916217T2 (de) 1998-11-27 2005-04-07 Mitsubishi Chemical Corp. Verfahren zur Herstellung von Maleinsäureanhydrid
GB9902452D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0000626D0 (en) * 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
PL366068A1 (en) * 2000-10-10 2005-01-24 Smithkline Beecham Corporation Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents
DE10153346A1 (de) 2001-10-29 2004-04-22 Grünenthal GmbH Substituierte Indole
WO2003048101A1 (en) 2001-11-30 2003-06-12 The Burnham Institute Induction of apoptosis in cancer cells
WO2003062392A2 (en) 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor
EP1501797B1 (en) * 2002-04-23 2009-08-05 Aventis Pharmaceuticals Inc. 3-(substituted amino)-1h-indole-2-carboxylic acid ester and 3-(substituted amino)-benzo[b]thiophene-2-carboxylic acid ester derivatives as interleukin-4 gene expression inhibitors
EP2476667B1 (en) * 2003-02-26 2014-07-16 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
WO2004092346A2 (en) * 2003-04-15 2004-10-28 The Regents Of The University Of California Small molecule inhibition of a pdz-domain interaction
SE0302035D0 (sv) * 2003-07-09 2003-07-09 Biolipox Ab New compound
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
ITMI20040874A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
CA2570363A1 (en) * 2004-06-18 2005-12-29 Biolipox Ab Indoles useful in the treatment of inflammation
EP1765775B1 (en) * 2004-06-18 2009-04-29 Biolipox AB Indoles useful in the treatment of inflammation
JP2008502670A (ja) * 2004-06-18 2008-01-31 バイオリポックス エービー 炎症の治療に有用なインドール類
WO2006041961A1 (en) * 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
FR2878849B1 (fr) 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
CA2594777A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflamation
AU2005325497A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
WO2007008627A2 (en) * 2005-07-07 2007-01-18 Abbott Laboratories Apoptosis promoters
PE20080767A1 (es) * 2006-08-31 2008-08-08 Smithkline Beecham Corp Derivados de acido 1-indol-2-carboxilico como moduladores de ppar
CN101743224A (zh) * 2007-04-16 2010-06-16 雅培制药有限公司 7-取代的吲哚mcl-1抑制剂
AU2009335818A1 (en) 2008-12-19 2011-07-21 Abbvie Inc. Compounds and methods of use
NZ593537A (en) 2008-12-19 2013-07-26 Genentech Inc Isoquinoline derivatives and methods of use

Also Published As

Publication number Publication date
JP5895011B2 (ja) 2016-03-30
WO2008130970A1 (en) 2008-10-30
JP5496876B2 (ja) 2014-05-21
US7981888B2 (en) 2011-07-19
CA2951295A1 (en) 2008-10-30
CN101711235A (zh) 2010-05-19
US20110263599A1 (en) 2011-10-27
DK2134685T3 (en) 2015-12-07
ES2550753T3 (es) 2015-11-12
EP2134685B1 (en) 2015-09-02
PL2134685T3 (pl) 2016-02-29
EP2134685A1 (en) 2009-12-23
CA2682354A1 (en) 2008-10-30
CA2951295C (en) 2020-04-28
US20090124616A1 (en) 2009-05-14
JP2014129396A (ja) 2014-07-10
JP2010524955A (ja) 2010-07-22
CA2682354C (en) 2016-12-13
MX2009011210A (es) 2009-10-30
US8853209B2 (en) 2014-10-07

Similar Documents

Publication Publication Date Title
PT2134685E (pt) Derivados de índole não substituídos na posição 7 como inibidores de mcl-1
IL201432A0 (en) 7 - substituted indole mcl - 1 inhibitors
HK1143367A1 (en) Quinazolin-oxime derivatives as hsp90 inhibitors hsp90 -
ZA200904138B (en) Substituted spirochromanone derivatives as acc inhibitors
EP2170076A4 (en) 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONDEACETYLASE INHIBITORS
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
HK1149762A1 (en) Substituted indole derivatives
PL2215075T3 (pl) Pochodne chinolinonu jako inhibitory PARP
ZA201104361B (en) Substituted dioxopiperidinyl phthalimide derivatives
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
HK1151291A1 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
HK1148283A1 (en) Heterocyclic derivatives
GB0905328D0 (en) Indole derivatives
IL202034A0 (en) Heterocyclic indazole derivatives
AP2743A (en) Macrocyclic indole derivatives useful as hepatitisC virus inhibitors
CR10879A (es) Cyclized derivatives as eg-5 inhibitors
IL202612A0 (en) Compositions comprising tryptophan hydroxylase inhibitors
IL211290A0 (en) New 2-amidothiadiazole derivatives
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
IL207225A0 (en) Indazole derivatives
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
ZA200905265B (en) Indole derivatives
ZA201002580B (en) Heterocyclic derivatives